Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AL 335/odalasvir/simeprevir - Janssen/Medivir

Next Previous
X
Search
Drug Profile

AL 335/odalasvir/simeprevir - Janssen/Medivir

Alternative Names: 3DAA FDC - Medivir; AL-335/odalasvir/simeprevir - Janssen/Medivir; JNJ-4178; odalasvir/simeprevir/AL-335 - Janssen/Medivir; simeprevir/AL-335/odalasvir - Janssen/Medivir

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen; Medivir AB
  • Class 3-ring heterocyclic compounds; Antivirals; Benzimidazoles; Cyclopropanes; Indoles; Pyrimidine nucleotides; Quinolines; Small molecules; Sulfonamides; Thiazoles; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Nov 2017 Janssen Research & Development completes the OMEGA-1 phase IIb trial for Hepatitis C in Belgium, Canada, Germany, Poland, Singapore and Spain (NCT02765490)
  • 23 Oct 2017 Efficacy data from the phase IIb OMEGA-1 trial in Hepatitis C, which met its primary endpoint, presented at the The Liver Meeting 2017, 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 20 Oct 2017 Safety data from the phase IIb OMEGA-1 trial in Hepatitis C presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top